Background Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic,
expensive, and has generally poor outcomes. We undertook an individual patient data meta-…

Background Extensively drug-resistant tuberculosis has been reported in 45 countries,
including countries with limited resources and a high burden of tuberculosis. We describe the …

Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs, …

Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly …

Background Chronic respiratory disease causes substantial global morbidity and mortality.
The contribution of pulmonary tuberculosis to the aetiology of chronic respiratory disease is …

Background. The treatment of extensively drug-resistant tuberculosis (XDR TB) presents a
major challenge. Second-line antimycobacterial drugs are less effective, more toxic, and more …

Background. Completing treatment for multidrug-resistant (MDR) tuberculosis (TB) may be
more challenging than completing first-line TB therapy, especially in resource-poor settings. …

Evidence of successful management of multidrug-resistant tuberculosis (MDRTB) is mainly
generated from referral hospitals in high-income countries. We evaluate the management of …

The Objective of this analysis was to identify predictors of death, failure, and default among
MDR-TB patients treated with second-line drugs in DOTS-plus projects in Estonia, Latvia, …

Background Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis have
emerged as major global health threats. WHO recommends contact investigation in close …